{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T14:17:44Z","timestamp":1795270664457,"version":"4.10.3"},"reference-count":56,"publisher":"American Association for Cancer Research (AACR)","issue":"13","funder":[{"name":"Tianjin Medical University Cancer institute and Hospital","award":["ZLJZZDYYWZL04"],"award-info":[{"award-number":["ZLJZZDYYWZL04"]}]},{"DOI":"10.13039\/501100015406","name":"Tianjin Municipal Science and Technology Bureau","doi-asserted-by":"publisher","award":["TJSJMYXYC-D2-039"],"award-info":[{"award-number":["TJSJMYXYC-D2-039"]}],"id":[{"id":"10.13039\/501100015406","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009812","name":"Chinese Society of Clinical Oncology","doi-asserted-by":"publisher","award":["Y-SY2021MS-0240"],"award-info":[{"award-number":["Y-SY2021MS-0240"]}],"id":[{"id":"10.13039\/501100009812","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Tianjin Medical University Cancer institute and Hospital","award":["TJYXZDXK-009A"],"award-info":[{"award-number":["TJYXZDXK-009A"]}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Recurrent abnormalities in immune surveillance\u2013related genes affect the progression of diffuse large B-cell lymphoma (DLBCL) and modulate the response to therapeutic interventions. CD58 interacts with the CD2 receptor on T cells and NK cells and is recurrently mutated and deleted in DLBCL, suggesting that it may play a role in regulating antitumor immunity. In this study, we comprehensively analyzed the genomic characteristics of CD58 through targeted next-generation sequencing, RNA sequencing (RNA-seq), whole-exome sequencing, and single-cell RNA-seq in patients with newly diagnosed DLBCL. The CD58 mutation rate was 9.1%, and the copy number loss rate was 44.7% among all enrolled patients with DLBCL. Notably, CD58 genetic alterations, along with low CD58 expression, significantly correlated with reduced rates of response to R-CHOP therapy and inferior progression-free survival and overall survival. Single-cell RNA-seq revealed that CD58 expression in tumor cells was negatively correlated with CD8+ T-cell exhaustion\/dysfunction status. Insufficient T-cell activation resulting from CD58 alterations could not be attributed solely to CD2 signaling. CD58 inhibited the activity of the JAK2\/STAT1 pathway by activating the LYN\/CD22\/SH2 domain\u2013containing phosphatase 1 (SHP1) axis, thereby limiting PDL1 and IDO expression. Elevated PDL1 and IDO expression in CD58-deficient DLBCL cells led to immune evasion and tumor-intrinsic resistance to chimeric antigen receptor T-cell therapy. Direct activation of CD58\u2013CD2 costimulatory signaling in combination with anti-PDL1 blockade or IDO inhibitor sensitized CD58-deficient DLBCL to chimeric antigen receptor T-cell therapy. Collectively, this work identified the multiple roles of CD58 in regulating antitumor immune responses in DLBCL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Loss of CD58 mediates immune evasion and therapy resistance in diffuse large B-cell lymphoma by upregulating PDL1 and IDO through LYN\/CD22\/SHP1 signaling, providing potential targets and therapeutic strategies to improve patient treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/0008-5472.can-23-2874","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T15:10:34Z","timestamp":1713453034000},"page":"2123-2140","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["CD58 Alterations Govern Antitumor Immune Responses by Inducing PDL1 and IDO in Diffuse Large B-Cell Lymphoma"],"prefix":"10.1158","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2526-0797","authenticated-orcid":false,"given":"Xiyue","family":"Xu","sequence":"first","affiliation":[{"name":"National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine and Department of Lymphoma, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0886-7168","authenticated-orcid":false,"given":"Yidan","family":"Zhang","sequence":"additional","affiliation":[{"name":"National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine and Department of Lymphoma, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9014-7724","authenticated-orcid":false,"given":"Yaxiao","family":"Lu","sequence":"additional","affiliation":[{"name":"National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine and Department of Lymphoma, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4972-2317","authenticated-orcid":false,"given":"Xiaoyan","family":"Zhang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology and Division of Pediatric Blood Diseases Center, Institute of Hematology and Blood Diseases Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Tianjin, China. 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7747-2039","authenticated-orcid":false,"given":"Cuicui","family":"Zhao","sequence":"additional","affiliation":[{"name":"National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine and Department of VIP Ward, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6846-0079","authenticated-orcid":false,"given":"Jiesong","family":"Wang","sequence":"additional","affiliation":[{"name":"National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine and Department of Lymphoma, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. 1"},{"name":"Department of Lymphoma and Head and Neck Oncology, College of Clinical Medicine for Oncology, Fujian Medical University, Fuzhou, China. 4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2935-4357","authenticated-orcid":false,"given":"Qingpei","family":"Guan","sequence":"additional","affiliation":[{"name":"National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine and Department of Lymphoma, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. 1"},{"name":"Department of Critical Care Medicine, Tianjin Cancer Hospital Airport Hospital, Tianjin, China. 5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5034-8879","authenticated-orcid":false,"given":"Yingfang","family":"Feng","sequence":"additional","affiliation":[{"name":"National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine and Department of Lymphoma, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1209-7446","authenticated-orcid":false,"given":"Meng","family":"Gao","sequence":"additional","affiliation":[{"name":"National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine and Department of Lymphoma, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1872-3584","authenticated-orcid":false,"given":"Jingwei","family":"Yu","sequence":"additional","affiliation":[{"name":"National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine and Department of Lymphoma, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7846-3579","authenticated-orcid":false,"given":"Zheng","family":"Song","sequence":"additional","affiliation":[{"name":"National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine and Department of Lymphoma, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5326-9678","authenticated-orcid":false,"given":"Xia","family":"Liu","sequence":"additional","affiliation":[{"name":"National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine and Department of Lymphoma, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3948-1405","authenticated-orcid":false,"given":"Zahra","family":"Golchehre","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, Tehran University of Medical Sciences, Tehran, Iran. 6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4088-4430","authenticated-orcid":false,"given":"Lanfang","family":"Li","sequence":"additional","affiliation":[{"name":"National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine and Department of Lymphoma, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2408-9732","authenticated-orcid":false,"given":"Weicheng","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden. 7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3634-5817","authenticated-orcid":false,"given":"Qiang","family":"Pan-Hammarstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden. 7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0091-0026","authenticated-orcid":false,"given":"Huilai","family":"Zhang","sequence":"additional","affiliation":[{"name":"National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine and Department of Lymphoma, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7663-2923","authenticated-orcid":false,"given":"Xianhuo","family":"Wang","sequence":"additional","affiliation":[{"name":"National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine and Department of Lymphoma, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2024]]},"reference":[{"key":"2026042014572948600_bib1","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"key":"2026042014572948600_bib2","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N Engl J Med"},{"key":"2026042014572948600_bib3","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ccr.2011.11.006","article-title":"Combined genetic inactivation of \u03b22-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma","volume":"20","author":"Challa-Malladi","year":"2011","journal-title":"Cancer Cell"},{"key":"2026042014572948600_bib4","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.immuni.2020.11.002","article-title":"Genome-wide screens identify lineage- and tumor-specific genes modulating MHC-I- and MHC-II-restricted immunosurveillance of human lymphomas","volume":"54","author":"Dersh","year":"2021","journal-title":"Immunity"},{"key":"2026042014572948600_bib5","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1182\/blood-2003-07-2365","article-title":"Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project","volume":"103","author":"Rimsza","year":"2004","journal-title":"Blood"},{"key":"2026042014572948600_bib6","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nature09754","article-title":"MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers","volume":"471","author":"Steidl","year":"2011","journal-title":"Nature"},{"key":"2026042014572948600_bib7","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1182\/blood-2017-11-764332","article-title":"Genetics of diffuse large B-cell lymphoma","volume":"131","author":"Pasqualucci","year":"2018","journal-title":"Blood"},{"key":"2026042014572948600_bib8","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1182\/blood-2015-11-683003","article-title":"Comprehensive characterization of programmed death ligand structural rearrangements in B-cell non-Hodgkin lymphomas","volume":"128","author":"Chong","year":"2016","journal-title":"Blood"},{"key":"2026042014572948600_bib9","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1182\/blood-2015-12-686550","article-title":"Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas","volume":"127","author":"Georgiou","year":"2016","journal-title":"Blood"},{"key":"2026042014572948600_bib10","doi-asserted-by":"crossref","first-page":"705260","DOI":"10.3389\/fimmu.2021.705260","article-title":"CD58 immunobiology at a glance","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"2026042014572948600_bib11","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41588-021-00779-1","article-title":"Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion","volume":"53","author":"Frangieh","year":"2021","journal-title":"Nat Genet"},{"key":"2026042014572948600_bib12","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","article-title":"Genetic and functional drivers of diffuse large B cell lymphoma","volume":"171","author":"Reddy","year":"2017","journal-title":"Cell"},{"key":"2026042014572948600_bib13","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"key":"2026042014572948600_bib14","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood.2019003535","article-title":"Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report","volume":"135","author":"Lacy","year":"2020","journal-title":"Blood"},{"key":"2026042014572948600_bib15","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"key":"2026042014572948600_bib16","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nbt.3192","article-title":"Spatial reconstruction of single-cell gene expression data","volume":"33","author":"Satija","year":"2015","journal-title":"Nat Biotechnol"},{"key":"2026042014572948600_bib17","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","article-title":"Fast, sensitive and accurate integration of single-cell data with Harmony","volume":"16","author":"Korsunsky","year":"2019","journal-title":"Nat Methods"},{"key":"2026042014572948600_bib18","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41556-022-00866-3","article-title":"A single-cell atlas of non-haematopoietic cells in human lymph nodes and lymphoma reveals a landscape of stromal remodelling","volume":"24","author":"Abe","year":"2022","journal-title":"Nat Cell Biol"},{"key":"2026042014572948600_bib19","doi-asserted-by":"crossref","first-page":"11613","DOI":"10.1073\/pnas.90.24.11613","article-title":"The CD58 (LFA-3) binding site is a localized and highly charged surface area on the AGFCC\u02b9C\u2033 face of the human CD2 adhesion domain","volume":"90","author":"Arulanandam","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026042014572948600_bib20","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1084\/jem.180.5.1861","article-title":"Interaction between human CD2 and CD58 involves the major beta sheet surface of each of their respective adhesion domains","volume":"180","author":"Arulanandam","year":"1994","journal-title":"J Exp Med"},{"key":"2026042014572948600_bib21","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1093\/nar\/gkg509","article-title":"SIFT: predicting amino acid changes that affect protein function","volume":"31","author":"Ng","year":"2003","journal-title":"Nucleic Acids Res"},{"key":"2026042014572948600_bib22","doi-asserted-by":"crossref","first-page":"180015","DOI":"10.1038\/sdata.2018.15","article-title":"ImmPort, toward repurposing of open access immunological assay data for translational and clinical research","volume":"5","author":"Bhattacharya","year":"2018","journal-title":"Sci Data"},{"key":"2026042014572948600_bib23","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1158\/2326-6066.CIR-18-0439","article-title":"Immune profiling and quantitative analysis decipher the clinical role of immune-checkpoint expression in the tumor immune microenvironment of DLBCL","volume":"7","author":"Xu-Monette","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"2026042014572948600_bib24","doi-asserted-by":"crossref","first-page":"110713","DOI":"10.1016\/j.celrep.2022.110713","article-title":"A single-cell atlas of diffuse large B cell lymphoma","volume":"39","author":"Ye","year":"2022","journal-title":"Cell Rep"},{"key":"2026042014572948600_bib25","doi-asserted-by":"crossref","first-page":"e004114","DOI":"10.1136\/jitc-2021-004114","article-title":"Genetic characteristics involving the PD-1\/PD-L1\/L2 and CD73\/A2aR axes and the immunosuppressive microenvironment in DLBCL","volume":"10","author":"Zhang","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026042014572948600_bib26","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.ccell.2021.08.011","article-title":"The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma","volume":"39","author":"Steen","year":"2021","journal-title":"Cancer Cell"},{"key":"2026042014572948600_bib27","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1158\/1078-0432.CCR-19-2803","article-title":"A four-chemokine signature is associated with a T-cell-inflamed phenotype in primary and metastatic pancreatic cancer","volume":"26","author":"Romero","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026042014572948600_bib28","doi-asserted-by":"crossref","first-page":"e159402","DOI":"10.1172\/JCI159402","article-title":"Multidimensional single-cell analysis identifies a role for CD2-CD58 interactions in clinical antitumor T cell responses","volume":"132","author":"Romain","year":"2022","journal-title":"J Clin Invest"},{"key":"2026042014572948600_bib29","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep"},{"key":"2026042014572948600_bib30","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1038\/s41375-018-0376-6","article-title":"Inflammation-induced glycolytic switch controls suppressivity of mesenchymal stem cells via STAT1 glycosylation","volume":"33","author":"Jitschin","year":"2019","journal-title":"Leukemia"},{"key":"2026042014572948600_bib31","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.cellsig.2003.08.015","article-title":"Distinct membrane localization and kinase association of the two isoforms of CD58","volume":"16","author":"Ariel","year":"2004","journal-title":"Cell Signal"},{"key":"2026042014572948600_bib32","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.cellsig.2009.02.022","article-title":"Signal transduction by CD58: the transmembrane isoform transmits signals outside lipid rafts independently of the GPI-anchored isoform","volume":"21","author":"Ariel","year":"2009","journal-title":"Cell Signal"},{"key":"2026042014572948600_bib33","first-page":"9","article-title":"Lyn tyrosine kinase: accentuating the positive and the negative","volume":"22","author":"Xu","year":"2005","journal-title":"Immunity"},{"key":"2026042014572948600_bib34","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1600-065X.2008.00758.x","article-title":"Multiple roles of Lyn kinase in myeloid cell signaling and function","volume":"228","author":"Scapini","year":"2009","journal-title":"Immunol Rev"},{"key":"2026042014572948600_bib35","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1182\/blood.2020006528","article-title":"CBL mutations drive PI3K\/AKT signaling via increased interaction with LYN and PIK3R1","volume":"137","author":"Belizaire","year":"2021","journal-title":"Blood"},{"key":"2026042014572948600_bib36","doi-asserted-by":"crossref","first-page":"e439","DOI":"10.1038\/emm.2017.256","article-title":"Integrin CD11b negatively regulates Mincle-induced signaling via the Lyn-SIRP\u03b1-SHP1 complex","volume":"50","author":"Zhang","year":"2018","journal-title":"Exp Mol Med"},{"key":"2026042014572948600_bib37","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.3389\/fimmu.2018.02276","article-title":"Ligand recognition determines the role of inhibitory B cell co-receptors in the regulation of B cell homeostasis and autoimmunity","volume":"9","author":"Tsubata","year":"2018","journal-title":"Front Immunol"},{"key":"2026042014572948600_bib38","doi-asserted-by":"crossref","first-page":"5844","DOI":"10.1182\/bloodadvances.2022007891","article-title":"CD58 loss in tumor cells confers functional impairment of CAR T cells","volume":"6","author":"Yan","year":"2022","journal-title":"Blood Adv"},{"key":"2026042014572948600_bib39","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood.2020005546","article-title":"Rosetting T cells in Hodgkin lymphoma are activated by immunological synapse components HLA class II and CD58","volume":"136","author":"Veldman","year":"2020","journal-title":"Blood"},{"key":"2026042014572948600_bib40","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ng.2873","article-title":"Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas","volume":"46","author":"Palomero","year":"2014","journal-title":"Nat Genet"},{"key":"2026042014572948600_bib41","doi-asserted-by":"crossref","first-page":"6129","DOI":"10.1158\/0008-5472.CAN-14-0643","article-title":"Molecular characterization of chronic-type adult T-cell leukemia\/lymphoma","volume":"74","author":"Yoshida","year":"2014","journal-title":"Cancer Res"},{"key":"2026042014572948600_bib42","doi-asserted-by":"crossref","first-page":"E14","DOI":"10.1002\/ajh.26392","article-title":"Comprehensive analysis of TP53 mutation characteristics and identification of patients with inferior prognosis and enhanced immune escape in diffuse large B-cell lymphoma","volume":"97","author":"Zhang","year":"2022","journal-title":"Am J Hematol"},{"key":"2026042014572948600_bib43","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.7150\/thno.25149","article-title":"Expansion of allogeneic NK cells with efficient antibody-dependent cell cytotoxicity against multiple tumors","volume":"8","author":"Sanchez-Martinez","year":"2018","journal-title":"Theranostics"},{"key":"2026042014572948600_bib44","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/S0301-472X(99)00079-X","article-title":"CD95\/Fas-triggered apoptosis of activated T lymphocytes is prevented by dendritic cells through a CD58-dependent mechanism","volume":"27","author":"Daniel","year":"1999","journal-title":"Exp Hematol"},{"key":"2026042014572948600_bib45","doi-asserted-by":"crossref","first-page":"eabn6373","DOI":"10.1126\/sciimmunol.abn6373","article-title":"Cis interactions between CD2 and its ligands on T cells are required for T cell activation","volume":"7","author":"Li","year":"2022","journal-title":"Sci Immunol"},{"issue":"Suppl 1","key":"2026042014572948600_bib46","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1182\/blood-2023-188468","article-title":"CD58 genetic alterations and its contribution to upregulation of PD-L1 and Ido via LYN\/CD22\/SHP1 axis in DLBCL","volume":"142","author":"Xu","year":"2023","journal-title":"Blood"},{"key":"2026042014572948600_bib47","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1038\/s41590-020-0770-x","article-title":"A dynamic CD2-rich compartment at the outer edge of the immunological synapse boosts and integrates signals","volume":"21","author":"Demetriou","year":"2020","journal-title":"Nat Immunol"},{"key":"2026042014572948600_bib48","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.ccell.2023.05.014","article-title":"The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity","volume":"41","author":"Ho","year":"2023","journal-title":"Cancer Cell"},{"key":"2026042014572948600_bib49","doi-asserted-by":"crossref","first-page":"585961","DOI":"10.3389\/fonc.2020.585961","article-title":"Prognostic implications of pan-cancer CMTM6 expression and its relationship with the immune microenvironment","volume":"10","author":"Zhao","year":"2020","journal-title":"Front Oncol"},{"key":"2026042014572948600_bib50","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.molimm.2020.01.006","article-title":"EZH2 inhibitors restore epigenetically silenced CD58 expression in B-cell lymphomas","volume":"119","author":"Otsuka","year":"2020","journal-title":"Mol Immunol"},{"key":"2026042014572948600_bib51","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.cell.2018.09.006","article-title":"A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade","volume":"175","author":"Jerby-Arnon","year":"2018","journal-title":"Cell"},{"key":"2026042014572948600_bib52","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41588-022-01268-9","article-title":"Multimodal single-cell and whole-genome sequencing of small, frozen clinical specimens","volume":"55","author":"Wang","year":"2023","journal-title":"Nat Genet"},{"key":"2026042014572948600_bib53","doi-asserted-by":"crossref","first-page":"100256","DOI":"10.1016\/j.modpat.2023.100256","article-title":"Detection of aberrant CD58 expression in a wide spectrum of lymphoma subtypes: implications for treatment resistance","volume":"36","author":"Younes","year":"2023","journal-title":"Mod Pathol"},{"key":"2026042014572948600_bib54","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/s41586-022-04439-0","article-title":"A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells","volume":"603","author":"Seung","year":"2022","journal-title":"Nature"},{"key":"2026042014572948600_bib55","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1158\/2326-6066.CIR-21-0218","article-title":"Immunomodulation of T- and NK-cell responses by a bispecific antibody targeting CD28 homolog and PD-L1","volume":"10","author":"Ramaswamy","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"2026042014572948600_bib56","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2020-139605","article-title":"CD58 aberrations limit durable responses to CD19 CAR in large B cell lymphoma patients treated with axicabtagene ciloleucel but can be overcome through novel CAR engineering","volume":"136","author":"Majzner","year":"2020","journal-title":"Blood"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/doi\/10.1158\/0008-5472.CAN-23-2874\/3443198\/can-23-2874.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/84\/13\/2123\/3469409\/can-23-2874.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/84\/13\/2123\/3469409\/can-23-2874.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T18:57:48Z","timestamp":1776711468000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/84\/13\/2123\/746136\/CD58-Alterations-Govern-Antitumor-Immune-Responses"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":56,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2024]]},"published-print":{"date-parts":[[2024,7,2]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-23-2874","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.7311386.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.7311386","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.26144636","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.26144636.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32701778","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]}}}